Evidence map›Paper›PMID 37378925›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2023

Association between Area under the Curve Estimated from Carboplatin Dose and Incidence of Severe Thrombocytopenia in Patients with Non-Hodgkin's Lymphoma on DeVIC Therapy.

Kengo Umehara, Shinya Takada, Kaori Yama, Kayo Yamagishi, Ko Ebata, Toshiya Sakai, Michiya Kobayashi, Hideki Sato, Kozo Mino, Kastuya Fujimoto

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Kengo UmeharaDepartment of Pharmacy, National Hospital Organization Hokkaido Cancer Center; 2-3-54 Kikusui 4, Shiroishi-ku, Sapporo, Hokkaido, Japan.ORCID 0000-0001-8722-7395
Shinya TakadaDepartment of Pharmacy, National Hospital Organization Hokkaido Cancer Center; 2-3-54 Kikusui 4, Shiroishi-ku, Sapporo, Hokkaido, Japan.ORCID 0000-0002-6845-5533
Kaori YamaDivision of Clinical Pharmacy, Department of Pharmacy, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 15-4-1 Maeda 7, Teine-ku, Sapporo, Hokkaido, Japan.
Kayo YamagishiDepartment of Pharmacy, National Hospital Organization Hokkaido Cancer Center; 2-3-54 Kikusui 4, Shiroishi-ku, Sapporo, Hokkaido, Japan.
Ko EbataDepartment of Hematology, National Hospital Organization Hokkaido Cancer Center; 2-3-54 Kikusui 4, Shiroishi-ku, Sapporo, Hokkaido, Japan.
Toshiya SakaiDepartment of Hematology, National Hospital Organization Hokkaido Cancer Center; 2-3-54 Kikusui 4, Shiroishi-ku, Sapporo, Hokkaido, Japan.
Michiya KobayashiDivision of Pharmaceutics (Clinical Pharmaceutics), School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, 1757 Kanazawa, Tobetsucho, Ishikari-gun, Hokkaido, Japan.
Hideki SatoDivision of Clinical Pharmacy, Department of Pharmacy, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 15-4-1 Maeda 7, Teine-ku, Sapporo, Hokkaido, Japan.
Kozo MinoDepartment of Pharmacy, National Hospital Organization Hokkaido Cancer Center; 2-3-54 Kikusui 4, Shiroishi-ku, Sapporo, Hokkaido, Japan.
Kastuya FujimotoDepartment of Hematology, National Hospital Organization Hokkaido Cancer Center; 2-3-54 Kikusui 4, Shiroishi-ku, Sapporo, Hokkaido, Japan.
National Hospital Organization Hokkaido Medical Center · JPSapporo National Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe degrees of adverse effects with carboplatin (CBDCA) are influenced by interindividual differences in the area under the curve (AUC), whereas renal function is not considered in the CBDCA dose design for dexamethasone, etoposide, ifosfamide, and CBDCA (DeVIC) therapy. We conducted this study to evaluate the association between the AUC and incidence of severe thrombocytopenia in patients treated with DeVIC with or without rituximab (DeVIC ± R).

methodsWe retrospectively analyzed clinical data for 36 patients with non-Hodgkin's lymphoma who received DeVIC ± R between May 2013 and January 2021 at the National Hospital Organization Hokkaido Cancer Center. The AUC of CBDCA (AUC

resultsThe median AUC

conclusionThis study suggests that the CBDCA dosing design considering renal function can reduce the risk of severe thrombocytopenia in DeVIC ± R therapy.

Indexed as

Lymphoma, Non-HodgkinThrombocytopeniaAntineoplastic Combined Chemotherapy ProtocolsArea Under CurveCarboplatinEtoposideHumansIncidenceRetrospective StudiesCarboplatinEtoposidearea under the blood concentration time curveCarboplatinnon-Hodgkin’ s lymphomasevere thrombocytopenia

Identifiers

PMID37378925
PMCPMC10505877
OpenAlexW4382345218

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.